Il-Yang Pharm. Co., Ltd.
Clinical trials sponsored by Il-Yang Pharm. Co., Ltd., explained in plain language.
A pharmaceutical company developing and marketing prescription drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug IY-828026 tested in healthy people for first time Results expected Mar 2027 (estimated)
- Can a new pill rescue patients when standard leukemia drugs stop working? Results expected Jun 2027 (estimated)
- Can a lower dose of a leukemia drug keep the disease in check? Results expected Jul 2027 (estimated)
-
New quadrivalent flu vaccine shows promise for little ones
Vaccine CompletedThis phase 3 study tests a new quadrivalent seasonal influenza vaccine in healthy infants aged 6 months to under 3 years. The goal is to see if the vaccine triggers a strong immune response and is safe compared to an existing flu shot. About 245 children will take part, and resea…
Phase 3 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Vaccine
Last updated Jul 10, 2026 00:00 UTC
-
Healthy men test drug combo in safety study
Knowledge-focused CompletedThis study looked at how two drugs, IY001 and IY002, affect each other in the body. It involved 43 healthy adult men who took the drugs separately and then together. The goal was to measure drug levels and check for any interactions. This is an early-stage trial focused on safety…
Phase 1 • Sponsor: Il-Yang Pharm. Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC